Clinical Trial Update: GOAT; Phase I Open Label Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Advanced Cancers [Phase 1]

View source ↗

Summary

Phase I open-label study of CGTG-102, a GM-CSF encoding oncolytic adenovirus, for advanced cancers, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• CGTG-102

Snippet

Sponsor: Baylor College of Medicine | Conditions: Tumors, Solid Tumors | Phase 1 | Status: WITHDRAWN